A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
Daniel J. Wallace, William Stohl, Richard A. Furie, Jeffrey R. Lisse, James D. McKay, Joan T. Merrill, Michelle A. Petri, Ellen M. Ginzler, W. Winn Chatham, W. Joseph McCune, Vivian Fernandez, Marc R.Volume:
61
Year:
2009
Language:
english
Pages:
11
DOI:
10.1002/art.24699
File:
PDF, 372 KB
english, 2009